Market Movers: Oriel Morrison interviews Jennifer Chow, MD and CEO of Chimeric Therapeutics (ASX:CHM)
Link copied to
Stockhead’s Market Movers video series features one-on-one interviews showcasing the major announcements of emerging ASX companies.
In this instalment, former CNBC, Sky News, and Bloomberg news anchor Oriel Morrison interviews Jennifer Chow, managing director and CEO of Chimeric Therapeutics (ASX:CHM).
Chimeric Therapeutics is the only clinical stage, cell therapy biotechnology company in Australia. The company’s focus is on discovering, developing and commercialising novel cell therapies with the most curative potential for patients.
To hear more, click above.